Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aytu Biopharma Inc (NQ: AYTU )

1.940 UNCHANGED
Streaming Delayed Price Updated: 10:32 AM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aytu Biopharma Inc

< Previous 1 2 3 4 5 6 7 8 Next >
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares jumped 72.4% to $20.55 amid increased retail investor interest in the stock. NextDecade Corporation (NASDAQ: NEXT... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Aytu BioPharma (NASDAQ:AYTU) stock increased by 19.36% to $6.41 during Tuesday's pre-market session. The market value of their outstanding shares is at $161.3... 
Via Benzinga
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Aytu Biopharma, Inc. (NASDAQ: AYTU) rose 37.8% to $7.40 in pre-market trading. Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) rose 23.5% to $3.89 in pre-market trading... 
Via Benzinga
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
Aytu BioPharma to Present at Upcoming June Investor Conferences
ENGLEWOOD, CO / ACCESSWIRE / May 25, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
30 Stocks Moving in Tuesday's Pre-Market Session
Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) shares rose 37.8% to $1.64 in pre-market trading after the company said it will receive $30 million in added payments during... 
Via Benzinga
The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
Recap: Aytu BioPharma Q3 Earnings
Shares of Aytu BioPharma (NASDAQ:AYTU) decreased in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 186.67% year over year to... 
Via Benzinga
Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights
- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company - - Added late-stage pediatric onset rare disease asset, protein kinase C β... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Earnings Scheduled For May 17, 2021
Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter. • U.S. Well Services (NASDAQ:... 
Via Benzinga
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving broadly lower for much of the week before coming back up strongly in the final session. Some of the... 
Via Benzinga
Exposures Product Safety
Aytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells
ENGLEWOOD, CO / ACCESSWIRE / May 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021
ENGLEWOOD, CO / ACCESSWIRE / May 10, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Alterity Therapeutics (NASDAQ:ATHE) stock rose 23.16% to $1.54 during Wednesday's pre-market session. The company's market cap stands at $53.4 million.... 
Via Benzinga
Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications Program initially targeting vascular Ehlers-Danlos Syndrome... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Product Safety
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.